# Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

> **NCT05656131** · PHASE2 · SUSPENDED · sponsor: **wang shusen** · enrollment: 80 (estimated)

## Conditions studied

- Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Fluzoparib+Camrelizumab

## Key facts

- **NCT ID:** NCT05656131
- **Lead sponsor:** wang shusen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-11-23
- **Primary completion:** 2026-03-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Why stopped:** Suspended
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656131, "Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05656131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*